Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.56 |
| ▸ | MAP2K1 | Q02750 | 15/20 | 0.46 |
| ▸ | MAP2K2 | P36507 | 8/20 | 0.46 |
| ▸ | PTPRC | P08575 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPRA | P18433 | 1/20 | 0.39 |
| ▸ | PTPRB | P23467 | 1/20 | 0.39 |
| ▸ | PTPRE | P23469 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3877145 | 0.86 | MEN1 (0.42) | IDO1MAP2K1MAP2K2MEN1KMT2A | |
| SCHEMBL3873028 | 0.86 | MAP2K1 (0.52) | IDO1MAP2K1MAP2K2MEN1KMT2A | |
| SCHEMBL3874109 | 0.79 | MAP2K1 (0.49) | MAP2K1MAP2K2 | |
| SCHEMBL3874114 | 0.79 | MAP2K1 (0.49) | MAP2K1MAP2K2 | |
| SCHEMBL6318708 | 0.79 | MAP2K1 (0.61) | MAP2K1MAP2K2 | |
| SCHEMBL3875114 | 0.76 | MAP2K1 (0.38) | MAP2K1MAP2K2MEN1KMT2A | |
| SCHEMBL5177704 | 0.76 | MAP2K1 (0.76) | IDO1MAP2K1MAP2K2 | |
| SCHEMBL6317554 | 0.76 | MAP2K1 (0.66) | MAP2K1MAP2K2 | |
| SCHEMBL5678007 | 0.75 | IDO1 (0.70) | IDO1MAP2K1MAP2K2PTPRCPTPN2 | |
| SCHEMBL4861357 | 0.72 | IDO1 (0.66) | IDO1MAP2K1MAP2K2PTPRCPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828184-B1 | [1,2,4]TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | MERCK SERONO SA (CH) | 2009-09-16 | — | — | EP | disclosed |
| US-20070299103-A1 | [1,2,4]Triazolo[4,3-A]Pyridine Derivatives for the Treatment of Hyperproliferative Diseases | MERCK SERONO SA (CH) | 2007-12-27 | — | — | US | disclosed |
| EP-1828184-A1 | [1,2,4]TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | LABORATOIRES SERONO S.A. (CH) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006058752-A1 | [1,2,4]TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | LABORATOIRES SERONO S.A. (CH) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299103-A1 | [1,2,4]Triazolo[4,3-A]Pyridine Derivatives for the Treatment of Hyperproliferative Diseases | CDK4, CDK3, BRAF | IDO1 1077/4885MAP2K1 114/4885MAP2K2 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.